Insmed Incorporated
INSM
Rang în acțiuni
#1110
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Preț acțiune
$95.08
Capitalizare de piață
$20.76B
Schimbare (1 zi)
-1.24%
Schimbare (1 an)
-42.64%
Țară
US
Tranzacționează Insmed Incorporated (INSM)
Categorie
Healthcare
EPS pentru Insmed Incorporated (INSM)
EPS la data de June 2026 TTM: $-4.11
Conform celor mai recente rapoarte financiare și prețului acțiunilor Insmed Incorporated, EPS-ul actual al companiei (TTM) este $-4.11. La sfârșitul anului 2023, compania avea un EPS de $-5.34 o creștere față de EPS-ului din 2022, care a fost de $-3.91.
Istoricul EPS pentru Insmed Incorporated din 2000 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| 2026 (TTM) | $-4.11 | -26.21% |
| 2024 | $-5.57 | 4.31% |
| 2023 | $-5.34 | 36.57% |
| 2022 | $-3.91 | 0.77% |
| 2021 | $-3.88 | 28.90% |
| 2020 | $-3.01 | 0.00% |
| 2019 | $-3.01 | -28.67% |
| 2018 | $-4.22 | 46.02% |
| 2017 | $-2.89 | 1.40% |
| 2016 | $-2.85 | 41.09% |
| 2015 | $-2.02 | 9.78% |
| 2014 | $-1.84 | 15.00% |
| 2013 | $-1.60 | 2.56% |
| 2012 | $-1.56 | -39.06% |
| 2011 | $-2.56 | 422.45% |
| 2010 | $-0.49 | -105.27% |
| 2009 | $9.30 | -826.56% |
| 2008 | $-1.28 | -26.44% |
| 2007 | $-1.74 | -70.46% |
| 2006 | $-5.89 | -29.88% |
| 2005 | $-8.40 | 20.86% |
| 2004 | $-6.95 | 140.48% |
| 2003 | $-2.89 | -73.75% |
| 2002 | $-11.01 | -2.65% |
| 2001 | $-11.31 | -74.06% |
| 2000 | $-43.60 | 0.00% |
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $17.32 | -521.41% |
US
|
|
| $-7.98 | 94.16% |
US
|
|
| $-5.29 | 28.71% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -774.94% |
NL
|
